Related Experiment Video

Updated: Jun 5, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Reversal effect of Dioscin on multidrug resistance in human hepatoma HepG2/adriamycin cells

Bu Tong Sun1, Li Hua Zheng, Yong Li Bao

  • 1National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, 130024, ChangChun, China.

European Journal of Pharmacology
|January 4, 2011
PubMed

Insights

Dioscin effectively reverses multidrug resistance in cancer by inhibiting the multidrug resistance gene 1 (MDR1) promoter activity. This natural compound shows potential as an adjunctive therapy to enhance chemotherapy efficacy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • Overexpression of the multidrug resistance gene 1 (MDR1) is a primary cause of MDR in human cancers.

Purpose of the Study:

  • To screen for natural compounds that can reverse multidrug resistance.
  • To investigate the potential of Dioscin as an MDR reversal agent targeting the MDR1 promoter.

Main Methods:

  • HEK293T cells were transfected with MDR1 promoter-luciferase reporter plasmids for drug screening.
  • A resistant HepG2/adriamycin cell line was used to validate Dioscin's efficacy.
  • Flow cytometry was employed to measure adriamycin accumulation and P-glycoprotein expression.

Main Results:

  • Dioscin inhibited MDR1 promoter activity in reporter assays.
  • Dioscin decreased the drug resistance of HepG2/adriamycin cells.
  • Dioscin significantly reduced P-glycoprotein expression and increased adriamycin accumulation in resistant cells.

Conclusions:

  • Dioscin is a potent multidrug resistance reversal agent.
  • Dioscin demonstrates potential as an adjunctive therapeutic agent for cancer chemotherapy.

More Related Videos

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...